Healthcare Sales & Marketing Network News: tanezumab

Searching News Database: tanezumab

HSMN NewsFeed - 19 Feb 2019
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Biopharmaceuticals

HSMN NewsFeed - 14 Nov 2018
Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality(TM) (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 24 Apr 2018
AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Dec 2017
FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Jan 2017
Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 24 Feb 2009
Pfizer Discontinues Development of Two Phase 3 Compounds
Biopharmaceuticals

Return to NewsFeed

FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!